Tag: investors

Industry veterans bring deep expertise in advanced reactor deployment, nuclear operations and regulatory licensing to support company’s U.S. growth

Uklon Store marks the company’s entry into e-commerce, introducing a scalable, asset-light and margin-accretive revenue stream that supports diversification, improves monetization of the existing user base, and underpins long-term growth and shareholder value.

Uklon Store, Uklon’s first move into everyday commerce, opens with flower deliveries in Kyiv. Customers can buy a bouquet in a few taps and have it delivered the same day by Uklon drivers.

Co-Founder and Chief Executive Officer Elias Sabo to Retire at Year End

BRATISLAVA, Slovakia and MONTREAL, June 11, 2026 (GLOBE NEWSWIRE) -- ESET Research’s tracking of OceanLotus activities from 2024–2026 has revealed a shift in operational focus as the Vietnam-aligned group adopted a more selective approach to external operations while placing increasing emphasis on domestic espionage. ESET researchers identified two distinct campaigns involving the SPECTRALVIPER backdoor: a supply-chain attack targeting stock market investors in Vietnam, and a prolonged espionage operation against a Vietnamese infrastructure and transport construction company.

Ebene Cybercity, Mauritius, June 11, 2026 (GLOBE NEWSWIRE) -- IUX has published a new article titled “5 ETF Risks to Understand During Volatile Markets,” examining several factors that may influence ETF performance during periods of heightened market uncertainty.

ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.

ZUG, Switzerland, June 11, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.